Histone deacetylase (HDAC) inhibitors constitute a new group of epigenetic agents that has
gained much attention in cancer drug development. Research in the field of epigenetics is …

Histone deacetylases (HDACs) are enzymes that play a key role in the epigenetic regulation
of gene expression by remodeling chromatin. Inhibition of HDACs is a prospective …

The class-I histone deacetylases (HDACs) HDAC1 and HDAC2 belong to a family of 11 zinc-
dependent human HDACs and are overexpressed in many cancers. Inhibitors of these …

Alterations in genomic and non-genomic mechanisms can disturb homeostasis and cause
severe human diseases. Histone deacetylases (HDACs) are epigenetic regulators which …

The opposing actions of histone acetyltransferases (HATs) and histone deacetylases
(HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling …

HDACs (histone deacetylases) are a group of enzymes that deacetylate histones as well as
non-histone proteins. They are known as modulators of gene transcription and are …

Histone deacetylase (HDAC), inhibitors represent a new class of targeted anti‐cancer
agents. Several of these compounds are in clinical trials with significant activity against a …

Histone deacetylase (HDAC) inhibitors show remarkable therapeutic potential for a variety of
disorders, including cancer, neurological disease, and cardiac hypertrophy. However, the …

Lysine acetylation is a conserved, reversible, post-translational protein modification
regulated by lysine acetyltransferases (KATs) and lysine deacetylases (KDACs; also known …

The interest in histone deacetylase (HDACa) inhibitors began almost 30 years ago during
some studies designed to understand why dimethyl sulfoxide (DMSO) caused terminal …